Strides Pharma Science Ltd is Rated Hold

Current Rating and Its Significance

MarketsMOJO’s 'Hold' rating for Strides Pharma Science Ltd indicates a neutral stance on the stock, suggesting that investors should neither aggressively buy nor sell at this juncture. This rating reflects a balanced view where the company exhibits certain strengths but also faces challenges that temper enthusiasm. The 'Hold' grade is supported by a Mojo Score of 58.0, which improved from a previous score of 40.0 when the rating was 'Sell'. This change in score and rating was recorded on 06 April 2026, signalling a shift in the company’s outlook based on evolving fundamentals and market conditions.

Here’s How the Stock Looks Today

As of 12 June 2026, Strides Pharma Science Ltd presents a mixed but cautiously optimistic profile. The company’s financial metrics and market performance reveal a nuanced picture that investors should carefully consider.

Quality Assessment

The quality grade for Strides Pharma is currently below average. This is primarily due to its weak long-term fundamental strength. The company’s average Return on Capital Employed (ROCE) stands at 8.83%, which is modest and indicates limited efficiency in generating returns from its capital base. Over the past five years, net sales have grown at an annual rate of 7.94%, while operating profit has increased by 11.02% annually. These growth rates, while positive, are not robust enough to classify the company as a high-quality growth stock. Additionally, the company’s debt servicing ability is a concern, with a Debt to EBITDA ratio of 1.90 times, signalling moderate leverage that could constrain financial flexibility.

Valuation Perspective

Valuation is a key factor supporting the 'Hold' rating. Currently, Strides Pharma is considered very attractively valued. The stock trades at an Enterprise Value to Capital Employed ratio of 2.3, which is below the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. This discount suggests that the market is pricing in some risks or uncertainties, but it also offers potential value for investors willing to hold the stock. The company’s ROCE for the half-year period is notably higher at 17.96%, indicating improved capital efficiency in the short term, which supports the valuation appeal.

Financial Trend and Profitability

The financial trend for Strides Pharma is very positive as of today. The company reported a remarkable 54.96% growth in net profit in the most recent quarter ending March 2026. This marks the eleventh consecutive quarter of positive results, underscoring consistent operational performance. Operating profit to interest coverage ratio is strong at 5.77 times, reflecting comfortable interest servicing capacity. The debt-equity ratio has improved to a low 0.57 times in the half-year period, signalling a healthier balance sheet. Despite these positives, it is important to note that over the past year, profits have declined by 14.9%, which tempers the overall financial outlook.

Technical Outlook

From a technical standpoint, the stock exhibits a mildly bullish trend. Recent price movements show some volatility, with a one-day decline of 0.34% and a one-week drop of 5.46%. However, the stock has delivered positive returns over longer periods, including +8.19% over three months, +11.70% over six months, and +15.91% over the past year. The year-to-date return stands at +9.27%, indicating resilience despite short-term fluctuations. These technical signals suggest that while the stock is not in a strong uptrend, it maintains a degree of upward momentum that supports a neutral rating.

Risks and Considerations

Investors should be mindful of certain risks associated with Strides Pharma. Notably, 27.27% of promoter shares are pledged, which can exert downward pressure on the stock price during market downturns. This factor adds a layer of risk that investors must weigh against the company’s operational improvements and valuation attractiveness.

What This Rating Means for Investors

The 'Hold' rating advises investors to maintain their current positions in Strides Pharma Science Ltd rather than initiating new purchases or selling off holdings. The company’s very attractive valuation and improving financial trends provide a foundation for potential upside, but the below-average quality metrics and risks related to promoter share pledging warrant caution. Investors should monitor upcoming quarterly results and market developments closely to reassess the stock’s outlook.

Summary of Key Metrics as of 12 June 2026

To recap, the stock’s performance and financial indicators as of today include:

• Mojo Score: 58.0 (Hold grade)
• Return on Capital Employed (ROCE): 8.83% average; 17.96% half-year high
• Net Sales growth (5 years CAGR): 7.94%
• Operating Profit growth (5 years CAGR): 11.02%
• Debt to EBITDA ratio: 1.90 times
• Debt-Equity ratio (half-year): 0.57 times
• Net Profit growth (latest quarter): +54.96%
• Stock returns: 1Y +15.91%, YTD +9.27%, 6M +11.70%, 3M +8.19%
• Promoter shares pledged: 27.27%

These figures illustrate a company with improving profitability and valuation appeal, balanced by structural challenges and market risks.

Looking Ahead

Investors considering Strides Pharma Science Ltd should weigh the company’s positive earnings momentum and attractive valuation against its moderate quality metrics and leverage concerns. The 'Hold' rating reflects this balanced outlook, suggesting that the stock may be suitable for investors seeking exposure to the pharmaceuticals sector without taking on excessive risk at this time.

Conclusion

In conclusion, Strides Pharma Science Ltd’s current 'Hold' rating by MarketsMOJO, updated on 06 April 2026, is supported by a combination of very positive financial trends, attractive valuation, and a mildly bullish technical stance, offset by below-average quality and certain risk factors. As of 12 June 2026, the stock presents a cautious opportunity for investors who prefer to maintain positions while monitoring future developments closely.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →